ESTRO 2024 - Abstract Book

S280

Brachytherapy - Gynaecology

ESTRO 2024

51 patients, with a median age of 55 years (31-80), median follow up of 129 months (6-177). Stage at presentation were IIB in 9 patients (17.6%), IIIB in 39 patients (76.5%) and IVA in 3 patients (5.9 %). Histology was squamous cell in all except two patients. OS was 66.66% (30/45), DFS of 66.22 % (28/45) and CSS was 82.22% (37/45). OS was 55.55% (5/9), 66.66% (22/33) and 100% (3/3) among stage IIB, IIIB and IVA respectively. Among the 45 patients, there was a total of 9 recurrences. local recurrences occurred in 3 patients of which one was in stage IIB & two were in stage IIIB. Out of 6 distant recurrences, 5 were in stage IIB and 1 was in stage IIIB. Late toxicity was observed among 21% (10/45) patients. Tubo ovarian abscess in 1 (2%), radiation cystitis in 1 (2%), radiation proctitis in 6 (13%), rectovaginal fistula in 2 (4%). Three patients had skeletal metastasis, visceral metastasis in one, extra pelvic nodal metastasis in two patients. There was no correlation of EQD2 dose to bladder, rectum & tumour for the occurrence of cystitis, proctitis and tumour control respectively.

Conclusion:

TPI- BT safely delivers desired high dose to the cervix and bilateral parametria as boost which results in better long term control of disease and comparable adjacent normal tissue toxicity. The patterns of failure seems to be no different after other local regional treatments for carcinoma cervix. Since there are trends of better long term control with TPI -BT as boost after concurrent CT + RT, study with larger number of patients is warranted to confirm the findings.

Keywords: Carcinoma cervix, interstitial brachytherapy,

References:

J. Fallon et al. / Gynecologic Oncology 144 (2017) 21–27

2891

Proffered Paper

Free and non-profit state-of-the-art education for countries with high burden of cervical cancer

Laura Motisi 1 , Sandeep Kamal 1 , Nuradh Joseph 2 , Ina Jürgenliemk Schulz 3 , Nadarajah Jeyakumaran 4 , Christian Kirisits 5 , Umesh Mahantshetty 6 , Taran Paulsen Hellebust 7 1 Zürich University Hospital, Radiation oncology, Zürich, Switzerland. 2 Ministry of Health – Sri Lanka, Oncology, Hambantota District, Sri Lanka. 3 University Medical Centre Utrecht, Radiation oncology, Utrecht, Netherlands. 4 National Cancer Institute, Oncology, Maharagama, Sri Lanka. 5 5Comprehensive Cancer Center, Medical University of Vienna, Radiation oncology, Vienna, Austria. 6 Homi Bhabha Cancer Hospital & Research Centre, Radiation oncology, Visakhapatnam, India. 7 Oslo University Hospital, The Radium Hospital, Medical Physics, Oslo, Norway

Purpose/Objective: